Brokerages Set CRISPR Therapeutics AG (NASDAQ:CRSP) Target Price at $64.24

by · The Markets Daily

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been assigned a consensus rating of “Hold” from the eighteen ratings firms that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and ten have assigned a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $64.2353.

Several research firms have recently commented on CRSP. Royal Bank Of Canada upped their target price on CRISPR Therapeutics from $42.00 to $50.00 and gave the company a “sector perform” rating in a report on Tuesday, November 11th. TD Cowen boosted their price objective on CRISPR Therapeutics from $40.00 to $45.00 and gave the company a “hold” rating in a research report on Friday, February 13th. Morgan Stanley reaffirmed an “underweight” rating and issued a $33.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, February 17th. Citizens Jmp cut their target price on CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating on the stock in a research note on Friday, January 30th. Finally, Chardan Capital boosted their price target on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a report on Saturday, February 14th.

Read Our Latest Analysis on CRSP

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $60.23, for a total transaction of $3,613,800.00. Following the sale, the chief executive officer owned 134,201 shares of the company’s stock, valued at $8,082,926.23. The trade was a 30.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 2,112 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $52.58, for a total value of $111,048.96. Following the transaction, the general counsel owned 85,115 shares of the company’s stock, valued at $4,475,346.70. This trade represents a 2.42% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 99,079 shares of company stock valued at $5,643,674 over the last three months. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Large investors have recently made changes to their positions in the business. Mcguire Capital Advisors Inc. acquired a new position in shares of CRISPR Therapeutics during the 4th quarter worth $25,000. Ramirez Asset Management Inc. acquired a new stake in CRISPR Therapeutics during the fourth quarter worth $26,000. Rothschild Investment LLC lifted its stake in CRISPR Therapeutics by 836.7% during the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after purchasing an additional 502 shares during the period. Thurston Springer Miller Herd & Titak Inc. raised its stake in CRISPR Therapeutics by 196.9% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock worth $30,000 after acquiring an additional 382 shares in the last quarter. Finally, Atlantic Union Bankshares Corp acquired a new position in CRISPR Therapeutics in the second quarter valued at about $33,000. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Price Performance

Shares of CRSP stock opened at $60.14 on Thursday. The firm has a fifty day moving average of $54.04 and a two-hundred day moving average of $57.29. The firm has a market cap of $5.77 billion, a P/E ratio of -9.22 and a beta of 1.72. CRISPR Therapeutics has a 1-year low of $30.04 and a 1-year high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last issued its earnings results on Thursday, February 12th. The company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.22). The firm had revenue of $0.86 million during the quarter, compared to analyst estimates of $4.72 million. CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.CRISPR Therapeutics’s revenue was down 97.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.01) EPS. On average, sell-side analysts expect that CRISPR Therapeutics will post -5.16 EPS for the current year.

CRISPR Therapeutics Company Profile

(Get Free Report)

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

Recommended Stories